To access this material please log in or register

Register Authorize

Cardioprotection in myocardial ischemia and reperfusion injury

Astashkin E. I., Glezer M. G.
State Budgetary Educational Institution of Higher Professional Education “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bldg. 2, Moscow 119991

Keywords: ischemia, myocardial reperfusion, cardioprotective effect, preconditioning, postconditioning, necrosis, apoptosis, energy metabolism

DOI: 10.18087/rhfj.2016.3.2237

The review is dedicated to the 30th anniversary of discovering the effect of ischemic preconditioning, one of fundamental mechanisms for cell protection in ischemia and reperfusion. The authors addressed mechanisms of cardiomyocyte injury in ischemia and reperfusion, which can result in heart cell death and development of HF. Physiological and pharmacological approaches to cardioprotection are described.
  1. Асташкин Е. И., Глезер М. Г. Энергетический обмен сердца. Вып. 4. Гибель клеток при ишемии / реперфузии сердца. Современные подходы к профилактике и лечению. – M.: Медиком, 2012. – 12с [Astashkin E. I., Glezer M. G. E`nergeticheskij obmen serdcza. Vy`p. 4. Gibel` kletok pri ishemii / reperfuzii serdcza. Sovremenny`e podxody` k profilaktike i lecheniyu. – M.: Medikom, 2012. – 12s].
  2. Turer A, Hill J. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010 Aug 1;106 (3):360–8.
  3. Murphy E, Steenbergen C. Mechanisms underlying acute protection fr om cardiac ischemia-reperfusion injury. Physiol Rev. 2008 Apr;88 (2):581–609.
  4. Talukder MA, Zweier JL, Periasamy M. Targeting calcium transport in ischaemic heart disease. Cardiovasc Res. 2009 Dec 1;84 (3):345–52.
  5. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion: a target cardioprotection. Cardiovasc Res. 2004 Feb 15;61 (3):372–85.
  6. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res. 2002 Aug 15;55 (3):534–43.
  7. Weiss JN, Korge P, Honda HM, Ping P. Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003 Aug 22;93 (4):292–301.
  8. Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. 2016 Apr;13 (4):193–209.
  9. Halestrap AP, Pereira GC, Pasdois P. The role of hexokinase in cardioprotection – mechanism and potential for translation. Br J Pharmacol. 2015 Apr;172 (8):2085–100.
  10. Weber NC. 'Conditioning the heart' – lessons we have learned from the past and future perspectives for new and old conditioning 'drugs'. Br J Pharmacol. 2015 Apr;172 (8):1909–12.
  11. Murry CE, Jennings RH, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74 (5):1124–36.
  12. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003 Aug;285 (2):H579–88.
  13. Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol. 2015 Jan 20;65 (2):177–95.
  14. Lim SY, Hausenloy DJ. Remote ischemic conditioning: from bench to bedside. Front Physiol. 2012 Feb 20;3:27.
  15. Aimo A, Borrelli C, Giannoni A, Pastormerlo LE, Barison A, Mirizzi G et al. Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences. World J Cardiol. 2015 Oct 26;7 (10):621–32.
  16. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015 Feb 13;116 (4):674–99.
  17. Foster MN, Coetzee WA. KATP channels in the cardiovascular system. Physiol Rev. 2016 Jan;96 (1):177–252.
  18. Downey JM, Krieg T, Cohen MV. Mapping preconditioning’s signaling pathways: an engineering approach. Ann N Y Acad Sci. 2008 Mar;1123:187–96.
  19. Kin H, Wang NP, Mykytenko J, Reeves J, Deneve J, Jiang R et al. Inhibition of myocardial apoptosis by postconditioning is associated with attenuation of oxidative stress-mediated nuclear factor-kappa B translocation and TNF alpha release. Shock. 2008 Jun;29 (6):761–8.
  20. Cao S, Liu Y, Wang H, Mao X, Chen J, Liu J et al. Ischemic postconditioning influences electron transport chain protein turnover in Langendorff-perfused rat hearts. Peer J. 2016 Feb 16;4: e1706.
  21. Wang G, Li X, Wang H, Wang Y, Zhang L, Zhang L et al. Later phase cardioprotection of ischemic post-conditioning against ischemia / reperfusion injury depends on iNOS and PI3K-Akt pathway. Am J Transl Res. 2015 Dec 15;7 (12):2603–11.
  22. Bice JS, Baxter GF. Postconditioning signalling in the heart: mechanisms and translatability. Br J Pharmacol. 2015 Apr;172 (8):1933–46.
  23. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May 5;357 (9266):1385–90.
  24. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J. 1996 Nov;17 (11):1646–56.
  25. Genoni M, Malacrida R, Sessa F, Siegrist P, Maggioni AP, Moccetti T. Long-term safety of an early ACE-inhibitor treatment of patients with acute myocardial infarction: results of the 3 year follow-up period on 696 Swiss patients randomized to the ISIS-4 trial. ISIS-Switzerland Study Group. Z Kardiol. 2000 Feb;89 (2):81–3.
  26. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327 (10):669–77.
  27. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997 Jan;18 (1):41–51.
  28. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333 (25):1670–6.
  29. Ambrosioni E, Borghi C, Magnani В. The effect of the angiotensin-converting-enzyme inhibitor on mortality and morbidity after anterior myocardial infarction. The survival of myocardial infarction long term evaluation (SMILE) Study Investigators. N Engl J Med. 1995 Jan 12;332 (2):80–5 [Ambrosioni E, Borghi C, Magnani V. The effect of the angiotensin-converting-enzyme inhibi­tor on mortality and morbidity after anterior myocardial infarction. The survival of myocardial infarction long term evaluation (SMILE) Study Investigators. N Engl J Med. 1995 Jan 12;332 (2):80–5].
  30. Maggioni AP, Fabbri G. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opin Pharmacother. 2005 Mar;6 (3):507–12.
  31. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348 (14):1309–21.
  32. Montalescot G, Pitt B, Lopez de SA, Hamm CW, Flather M, Verheugt F et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014 Sep 7;35 (34):2295–302.
  33. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007 Oct 27;370 (9597):1483–93.
  34. Thuc LC, Teshima Y, Takahashi N, Nagano-Torigoe Y, Ezaki K, Yufu K et al. Mitochondrial K (ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection. Apoptosis. 2010 Jun;15 (6):669–78.
  35. Rajtík T, Čarnická S, Szobi A, Mesárošová L, Máťuš M, Švec P et al. Pleiotropic effects of simvastatin are associated with mitigation of apoptotic component of cell death upon lethal myocardial reperfusion-induced injury. Physiol Res. 2012;61 (Suppl 2):S33–41.
  36. Yao L, Chen GP, Lu X, Zheng LR, Mou Y, Hu SJ. Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats. Basic Res Cardiol. 2009 May;104 (3):258–68.
  37. Глезер М. Г., Асташкин Е. И., Новикова М. В. Лечение стабильной стенокардии: современное состояние вопроса. Фарматека. 2013;18:31–8 [Glezer M. G., Astashkin E. I., Novikova M. V. Lechenie stabil`noj stenokardii: sovremennoe sostoyanie voprosa. Farmateka. 2013;18:31–8].
  38. Yang Y, Mou Y, Hu SJ, Fu M. Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins. Eur J Heart Fail. 2009 Jan;11 (1):6–13.
  39. Eleawa SM, Alkhateeb M, Ghosh S, Al-Hashem F, Shatoor AS, Alhejaily A, Khalil MA. Coenzyme Q10 protects against acute consequences of experimental myocardial infarction in rats. Int J Physiol Pathophysiol Pharmacol. 2015 Mar 20;7 (1):1–13.
  40. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014 Dec;2 (6):641–9.
  41. Atar D, Arheden H, Berdeaux A, Bonnet JL, Carlsson M, Clemmensen P et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-eleva­tion myocardial infarction: MITOCARE study results. Eur Heart J. 2015 Jan 7;36 (2):112–9.
  42. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015 Sep 10;373 (11):1021–31.
  43. Асташкин Е. И., Глезер М. Г. Механизм действия миокардиальных цитопротекторов. Новый взгляд. Энергетический обмен сердца. Вып. 3. – М.: Медиком, 2010. – 12c [Astashkin E. I., Glezer M. G. Mexanizm dejstviya miokardial`ny`x czitoprotektorov. Novy`j vzglyad. E`nergeticheskij obmen serdcza. Vy`p. 3. – M.: Medikom, 2010. – 12c].
  44. Vinokurov MG, Astashkin EI, Yurinskaya MM, Glezer MG, Sobolev KE, Grachev SV. Trimetazidine blocks store-operated Ca2+ channels in HL-60 and THP-1 cell lines and inhibits the secretion of tumor necrosis factor. Dokl Biol Sci. 2011 Nov-Dec;441:417–20.
  45. Винокуров М. Г., Асташкин Е. И., Юринская М. М., Глезер М. Г., Соболев К. Э., Грачёв С. В. Триметазидин блокирует депо-регулируемые Cа2+-каналы в перевиваемых фагоцитах человека и снижает секрецию фактора некроза опухоли. Доклады Академии Наук. 2011;441 (3):410–3 [Vinokurov M. G., Astashkin E. I., Yurinskaya M. M., Glezer M. G., Sobolev K. E`., Grachyov S. V. Trimetazidin blokiruet depo-reguliruemy`e Ca2+-kanaly` v pereviva­emy`x fagoczitax cheloveka i snizhaet sekrecziyu faktora nekroza opuxoli. Doklady` Akademii Nauk. 2011;441 (3):410–3].
  46. Dehina L, Vaillant F, Tabib A, Bui-Xuan B, Chevalier P, Dizerens N et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386 (3):205–15.
  47. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology. 1993 Jun;46 (6):324–31.
  48. Khan M, Meduru S, Mostafa M, Khan S, Hideg K, Kuppusamy P. Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther. 2010 May;333 (2):421–9.
  49. Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W et al. The protective effect of trimetazidine on myocardial ische­mia / reperfusion injury through activating AMPK and ERK signa­ling pathway. Metabolism. 2016 Mar;65 (3):122–30.
  50. Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl Res. 2007 Mar;149 (3):152–60.
  51. Yin RX, Liang WW, Liu TW, Tao XZ, Zhu LG, Al-Ghazali R. Inhibitory effect of trimetazidine on cardiac myocyte apoptosis in rabbit model of ischemia-reperfusion. Chin Med Sci J. 2004 Dec;19 (4):242.
  52. Yang Q, Yang K, Li AY. Trimetazidine protects against hypoxia-reperfusion-induced cardiomyocyte apoptosis by increasing microRNA-21 expression. Int J Clin Exp Pathol. 2015 Apr 1;8 (4):3735–41.
  53. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011 Feb;97 (4):278–86.
  54. Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One. 2014 May 5;9 (5):e94660.
  55. Асташкин Е. И., Глезер М. Г. Роль L-карнитина в энергетическом обмене кардиомиоцитов и лечении заболеваний сердечно-сосудистой системы. Кардиология и сердечно-сосудистая хирургия. 2012;5 (6):58–65 [Astashkin E. I., Glezer M. G. Rol` L-karnitina v e`nergeticheskom obmene kardiomioczitov i lechenii zabolevanij serdechno-sosudistoj sistemy`. Kardiologiya i serdechno-sosudistaya xirurgiya. 2012;5 (6):58–65].
  56. Iliceto S, Scrutinio D, Bruzzi P, D’Ambrosio G, Boni L, Biase M et al. Effect of L-carnitine administration on left ventricular remo­deling after acute anterior myocardial infarction: the L–Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol. 1995 Aug;26 (2):380–7.
  57. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. 2006;106 (4):215–23.
  58. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005 Jan 26;293 (4):437–46.
  59. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D’Agostino RB et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012 May 9;307 (18):1925–33.
  60. Bothe W, Olschewski M, Beyersdorf F, Doenst T. Glucose-insulin-potassium in cardiac surgery: a meta-analysis. Ann Thorac Surg. 2004 Nov;78 (5):1650–7.
  61. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962 Feb;9:166–81.
  62. Maulik M, Maulik SK, Kumari R. Importance of timing of magnesium administration: a study on the isolated ischemic reperfused rat heart. Magnes Res. 1999 Mar;12 (1):37–42.
  63. Matsubara T, Minatoguchi S, Matsuo H, Hayakawa K, Segawa T, Matsuno Y et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000 Feb;35 (2):345–51.
  64. Matsuo H, Watanabe S, Segawa T, Yasuda S, Hirose T, Iwama M et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel ope­ner nicorandil. Eur Heart J. 2003 Jul;24 (14):1296–303.
  65. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil-induced preconditioning as evidenced by troponin T measurements after coronary angioplasty in patients with stable angina pectoris. Jpn Heart J. 2002 Sep;43 (5):443–53.
  66. Wang A, Chen F, Xie Y, Guo Z, Yu Y. Protective mechanism of nicorandil on rat myocardial ischemia-reperfusion. J Cardiovasc Med (Hagerstown). 2012 Aug;13 (8):511–5.
  67. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, Matsubara T. Impact of a single intravenous administration of nico­randil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005 Aug 30;112 (9):1284–8.
  68. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J. 2009 May;73 (5):925–31.
  69. Wu M, Huang Z, Xie H, Zhou Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One. 2013 Oct 22;8 (10):e78231.
  70. Ono H, Osanai T, Ishizaka H, Hanada H, Kamada T, Onodera H et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am Heart J. 2004 Oct;148 (4):E15.
  71. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol. 2004 Apr;286 (4):H1273–80.
  72. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999 Mar;33 (3):654–60.
  73. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs. 2000 Oct;60 (4):955–74.
  74. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the KATP channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J. 1999 Jan;20 (1):51–7.
  75. Sakata Y, Kodama K, Komamura K, Lim YJ, Ishikura F, Hirayama A et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J. 1997 Jun;133 (6):616–21.
  76. Yasuda T, Hashimura K, Matsuura Y, Kato Y, Ueda T, Mori I, Kijima Y. Nicorandil, a hybrid between nitrate and ATP-sensitive potassium channel opener, preconditions human heart to ischemia during percutaneous transluminal coronary angioplasty. Jpn Circ J. 2001 Jun;65 (6):526–30.
  77. Singh M, Shah T, Khosla K, Singh P, Molnar J, Khosla S, Arora R. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis. 2012 Jun;6 (3):101–14.
  78. Aung Naing K, Li L, Su Q, Wu T. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2013 Jun 4;6: CD009503.
  79. Desmet W, Bogaert J, Dubois C, Sinnaeve P, Adriaenssens T, Pappas C et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011 Apr;32 (7):867–77.
  80. Fokkema ML, Vlaar PJ, Vogelzang M, Gu YL, Kampinga MA, de Smet BJ et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009 Aug;2 (4):323–9.
  81. Niccoli G, Rigattieri S, De Vita MR, Valgimigli M, Corvo P, Fabbiocchi F et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013 Jun;6 (6):580–9.
  82. Nazir SA, Khan JN, Mahmoud IZ, Greenwood JP, Blackman DJ, Kunadian V et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction du­ring primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials. 2014 Sep 25;15:371.
  83. Gao Q, Yang B, Guo Y, Zheng F. Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2015 Aug;94 (32):e1279.
  84. Wall T, Califf R, Blankenship J, Talley J, Tannenbaum M, Schwaiger M et al. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation. 1994 Jul;90 (1):114–20.
  85. Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation. 1997 Jul 1;96 (1):192–201.
  86. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction (LIM IT AMI) study. Circulation. 2001 Dec 4;104 (23):2778–83.
  87. Hansen A, Kumar A, Wolf D, Frankenbergerova K, Filusch A, Gross ML et al. Evaluation of cardioprotective effects of recombinant so­luble P-selectin glycoprotein ligand-immunoglobulin in myocardial ischemia-reperfusion injury by real-time myocardial contrast echocardiography. J Am Coll Cardiol. 2004 Aug 18;44 (4):887–91.
  88. Tardif JC, Tanguay JF, Wright SR, Duchatelle V, Petroni T, Grégoire JC et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013 May 21;61 (20):2048–55.
  89. Rusnak JM, Kopecky SL, Clements IP, Gibbons RJ, Holland AE, Peterman HS et al. An anti-CD11 / CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (FESTIVAL study). Am J Cardiol. 2001 Sep 1;88 (5):482–7.
  90. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11 / CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: results of the HALT-MI study. J Am Coll Cardiol. 2002 Oct 2;40 (7):1199–204.
  91. Dirksen MT, Laarman G, van 't Hof AW, Guagliumi G, Tonino WA, Tavazzi L et al. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. Eur Heart J. 2004 Mar;25 (5):392–400.
  92. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003 Sep 9;108 (10):1176–83.
  93. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003 Sep 9;108 (10):1184–90.
  94. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes Jr D, O'Neill WW et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007 Jan 3;297 (1):43–51.
  95. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011 May 11;305 (18):1863–72.
  96. Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol. 2011 Jun 2;149 (2):216–20.
  97. Prunier F, Bière L, Gilard M, Boschat J, Mouquet F, Bauchart JJ et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012 Feb;163 (2):200–7.e1.
  98. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. J Pineal Res. 2010 Aug;49 (1):14–22.
  99. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ, Jimenez-Sosa A. A unicenter, randomized, double-blind, parallel-group, placebo controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemp Clin Trials. 2007 Jul;28 (4):532–9.
Astashkin E. I., Glezer M. G. Cardioprotection in myocardial ischemia and reperfusion injury. Russian Heart Failure Journal. 2016;17 (3):189–200

To access this material please log in or register

Register Authorize
Ru En